Isolated limb perfusion in regional melanoma.
Adjuvant perfusion to excision of a primary melanoma cannot be recommended because of its limited effect. In patients who have frequently recur-ring resectable locoregional melanoma, perfusion may provide valuable loco-regional disease control by decreasing the number of recurrences and lesions per recurrence. Randomized studies are needed to further establish the role of perfusion as an adjuvant treatment for resectable recurrences of melanoma. Unresectable limb melanoma is the primary indication for perfusion. Better response rates tend to be seen when TNF-a is used in patients who have a high tumor load. Repeat perfusion is feasible, resulting in response rates similar to those of a first perfusion for locoregional melanoma. Older age itself is not a contraindication for perfusion. The long-term health-related quality of life of survivors of melanoma who underwent treatment with perfusion is comparable to that of their healthy peers in the general Dutch population.
Noorda
Eva M
EM
Department of Surgery, Slotervaart Hospital, Louwesweg 6, Amsterdam 100 BK, the Netherlands. cheno@slz.nl
Vrouenraets
Bart C
BC
Nieweg
Omgo E
OE
Kroon
Bin B R
BB
D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D000075202:Contraindications; D006801:Humans; D035002:Lower Extremity / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control; D009367:Neoplasm Staging; D010477:Perfusion; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D034941:Upper Extremity / Q000473:pathology